Critical clinical gaps in cancer precision nanomedicine development

Area of Science:

• Nanomedicine
• Cancer Research
• Precision Medicine

Background:

• Active targeting strategies are crucial in nanomedicine for cancer treatment.
• Personalizing nanomedicine based on patient omics data faces challenges in selecting appropriate targeting ligands and matrix materials.
• Current literature indicates a gap in selecting nanoparticulate components based on individual cancer omics profiles.

Purpose of the Study:

• To address the challenges in selecting targeting ligands and matrix materials for personalized nanomedicine.
• To highlight the influence of patient demographics (age, gender, ethnicity, geography) on cancer-related molecular targets.
• To emphasize the need for omics analysis in nanomedicine development for effective cancer treatment.

Main Methods:

• Review of nanomedicine literature from the past five years focusing on material selection.
• Analysis of factors influencing the expression of cancer cellular target receptors and metabolizing enzymes.
• Correlation of patient omics data with nanomedicine component selection.

Main Results:

• Nanoparticulate targeting ligand and matrix material selection is not currently based on patient-specific cancer omics profiles.
• Patient-specific metabolizing enzymes can prematurely degrade nanomedicine components, and targeting ligands may not match overexpressed cancer cell receptors.
• Individual omics analysis of metabolizing enzymes and cell surface receptors is essential.

Conclusions:

• Personalized nanomedicine development requires integrating patient omics data for informed selection of targeting ligands and matrix materials.
• Addressing patient-specific factors like enzyme expression and receptor profiles is critical for successful nanomedicine efficacy.
• Omics-driven selection facilitates the realization of personalized nanomedicine strategies in cancer therapy.